Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable ‐drug‐naïve elderly or renal impaired patients with type 2 diabetes in the United States

ConclusionRegardless of age or renal function, the benefits of EQW relative to BI treatment are improved glycaemic control and increased weight loss, which should be weighed against the increased risk of gastrointestinal symptoms.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fdom.13175

Source: Diabetes, Obesity and Metabolism - January 3, 2018 Category: Endocrinology Authors: Anita M. Loughlin, Qing Qiao, Anthony P. Nunes, Peter Öhman, Stephen Ezzy, Laura Yochum, C. Robin Clifford, Robert Gately, David D. Dore, John D. Seeger Tags: ORIGINAL ARTICLE Source Type: research